Insertional mutagenesis in a HER2-positive breast cancer model reveals ERAS as a driver of cancer and therapy resistance

Personalized medicine for cancer patients requires a deep understanding of the underlying genetics that drive cancer and the subsequent identification of predictive biomarkers. To discover new genes and pathways contributing to oncogenesis and therapy resistance in HER2+ breast cancer, we performed...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikink, Gerjon J., Boer, Mandy, Bakker, Elvira R. M., Vendel-Zwaagstra, Annabel, Klijn, Chris, ten Hoeve, Jelle, Jonkers, Jos, Wessels, Lodewyk F., Hilkens, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168451/
https://www.ncbi.nlm.nih.gov/pubmed/29326437
http://dx.doi.org/10.1038/s41388-017-0031-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168451/
https://www.ncbi.nlm.nih.gov/pubmed/29326437
http://dx.doi.org/10.1038/s41388-017-0031-0

Ejemplares similares